Overview
NICE is unable to make a recommendation about the use in the NHS of daratumumab, with lenalidomide and dexamethasone, for treating relapsed or refractory multiple myeloma because no evidence submission was received from Janssen-Cilag.
Last reviewed: 5 July 2017
Next review: We will review this decision if the company decides to make a submission.